Citations

Showing 10 of 108081 citations.

IgM myeloma: A multicenter retrospective study of 134 patients
Castillo, Jorge J. , Brožová, Lucie , Czepiel, Jacek , Dávila, Julio , Ghobrial, Irene M. , Gozzetti, Alessandro , Gustine, Joshua , Hájek, Roman , Jayabalan, David , Laubach, Jacob P. , Lewicka, Barbara , Maisnar, Vladimír , Manasanch, Elisabet E. , Moreau, Philippe , Nahi, Hareth , Niesvizky, Rubén, Paba‐Prada, Claudia E., Pika, Tomáš, Pour, Luděk , Reagan, John L. , Richardson, Paul G. , Shah, Jatin J., Špıčka, Ivan , Vij, Ravi , Jurczyszyn, Artur , Crusoé, Edvan de Queiroz , Dispenzieri, Angela , Eveillard, Marion , Fiala, Mark A. , Hungria, Vânia , Jarkovský, Jiří , Morgan, Elizabeth A. , Richardson, Paul Gerard Guy , Waszczuk‐Gajda, Anna , Gertz, Morie A. , Hajek, Roman , Moreau, Philippe , Castillo, Jorge J , Ghobrial, Irene M , Gozzetti, Alessandro , Nahi, Hareth

Mayo Clinic

American Journal of Hematology | April 6, 2017 | Volume: 92 | Issue: 8 | Pages: 746-751

10.1002/ajh.24753 | PMID 28383205 Get It

AbstractIgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.
Motivation, Perception, and Treatment Beliefs in the Myocardial Infarction Genes (MI‐GENES) Randomized Clinical Trial
Kattel, Sharma , Onyekwelu, Tochukwu, Brown, Sherry‐Ann , Jouni, Hayan, Austin, Erin , Kullo, Iftikhar J.

Mayo Clinic

Journal of Genetic Counseling | April 6, 2017 | Volume: 26 | Issue: 5 | Pages: 1153-1161

10.1007/s10897-017-0092-9 | PMID 28386791 Get It

AbstractLittle is known about individuals’ motivation, perception, and treatment beliefs towards the use of genetic information in risk estimates for coronary heart disease (CHD). In this study, participants at intermediate 10‐year risk of CHD were randomized to receive either their estimated conventional risk score (CRS) alone, or a CRS and a genetic risk score (GRS), by a genetic counselor. Surveys on motivation to participate in and perception of genetic testing for CHD were administered at 3 months and treatment beliefs at 6 months following risk disclosure. Survey responses used Likert scales. Linear and logistic regression were used for analysis. Overall, motivation to participate in genomic clinical trials was favorable and did not differ between the CRS and GRS groups (16.95 ± 0.82 vs. 17.58 ± 0.83, p = 0.091), but participants who initially received their GRS indicated a greater desire to find ways to improve health as a reason for participation (OR: 0.53 (95%CI: 0.29, 0.94), p = 0.028). Perception of genetic testing was also favorable in both groups (15.29 ± 0.39 vs. 15.12 ± 0.40, p = 0.835). Participants who initially received their GRS were more inclined to recommend genetic testing to family and friends (9.95 ± 1.88 vs. 10.52 ± 2.17, p = 0.023). In the MI‐GENES study, motivation to participate in and perception of genetic testing among study participants were overall favorable. Genetic risk disclosure was associated with increased motivation to recommend genetic testing to family and friends.
Bostwick, David G., Lieber, Michael M., Jenkins, Robert B. , Qian, J.

Mayo Clinic

The Japanese Journal of Urology | April 6, 2017 | Volume: 89 | Issue: 2 | Pages: 267

10.5980/jpnjurol.89.267_2 Get It

HA, Guess, CJ, Girman, SJ, Jacobsen, MM, Lieber, Ha, Guess, Girman, Cynthia J. , Jacobsen, S. J.

Mayo Clinic

The Japanese Journal of Urology | April 6, 2017 | Volume: 88 | Issue: 2 | Pages: 316

10.5980/jpnjurol.88.316_4 Get It

CJ, Girman, HA, Guess, MM, Lieber, Girman, Cynthia J. , Ha, Guess

Mayo Clinic

The Japanese Journal of Urology | April 6, 2017 | Volume: 87 | Issue: 2 | Pages: 468

10.5980/jpnjurol.87.468_1 Get It

Lieber, Michael M., Jenkins, Robert B.

Mayo Clinic

The Japanese Journal of Urology | April 6, 2017 | Volume: 87 | Issue: 2 | Pages: 283

10.5980/jpnjurol.87.283_1 Get It

Hogen, Kristine L., Tindall, D. J., Young, Charles Y.F.

Mayo Clinic

The Japanese Journal of Urology | April 6, 2017 | Volume: 86 | Issue: 3 | Pages: 427

10.5980/jpnjurol.86.427_2 Get It

Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Calhoun, David A. , Lenders, Jacques W.M. , Textor, Stephen C., Young, William F. , Stowasser, Michael

Mayo Clinic

Endocrine Reviews | April 6, 2017 | Volume: 38 | Issue: 2 | Pages: 103-122

10.1210/er.2017-00054 Get It

Rotavirus Vaccine Schedules and Vaccine Response Among Infants in Low- and Middle-Income Countries: A Systematic Review
Gruber, Joann F. , Gruber, Lucinda , Weber, Rachel Palmieri , Becker‐Dreps, Sylvia , Funk, Michele Jönsson , Gruber, Lucinda M

Mayo Clinic

Open Forum Infectious Diseases | April 6, 2017 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/ofid/ofx066 | PMID 28567431 Get It

Abstract Background Rotavirus vaccine schedules may impact vaccine response among children in low- and middle-income countries (LMICs). Our objective was to review the literature evaluating the effects of monovalent (RV1) or pentavalent rotavirus vaccines schedules on vaccine response. Methods We searched PubMed, Web of Science, Embase, and ClinicalTrials.gov for eligible trials conducted in LMICs comparing ≥2 vaccine schedules and reporting immunologic response or efficacy. We calculated seroconversion proportion differences and geometric mean concentration (GMC) ratios with 95% confidence intervals. Results We abstracted data from 8 eligible trials of RV1. The point estimates for seroconversion proportions difference ranged from −0.25 to −0.09 for the 6/10-week schedule compared with 10/14. The range for the 6/10/14- compared with 10/14-week schedule was −0.02 to 0.10. Patterns were similar for GMC ratios and efficacy estimates. Conclusions The commonly used 6/10-week RV1 schedule in LMICs may not be optimal. Further research on the effect of rotavirus schedules using clinical endpoints is essential.